AbCellera

Ended the quarter with over $565 million in total cash balances and marketable securities, providing over $675 million in total available liquidity to execute on AbCellera s strategy.

SEC original ↗AbCellera — Earnings release (8-K exhibit)EX-99Aug 5, 2026

Available Liquidity over $565 million in total cash balances and marketable securities, and $110 million in available non-dilutive government funding, bringing total available liquidity to over $675 million to execute on AbCellera's strategy.

SEC original ↗AbCellera — Earnings release (8-K exhibit)EX-99Aug 5, 2026

AbCellera (Nasdaq ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women s health, immunology, oncology, and more.

SEC original ↗AbCellera — Earnings release (8-K exhibit)EX-99Aug 5, 2026

All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives 2 for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R D government contributions).

SEC original ↗AbCellera — Earnings release (8-K exhibit)EX-99Aug 5, 2026

All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions).

SEC original ↗AbCellera — Presentation / slide deck (8-K exhibit)EX-99Aug 5, 2026

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements.

SEC original ↗AbCellera — Earnings release (8-K exhibit)EX-99Aug 5, 2026

These risks, uncertainties, other factors, and definition of our business metrics are described under Risk Factors, Management s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in the documents we file with the Securities and Exchange Commission from time to time.

SEC original ↗AbCellera — Earnings release (8-K exhibit)EX-99Aug 5, 2026

htm EX-99.2 a2026q2fybusinessupdatea CO PY RI GH T © A BC EL LE RA AUGUST 5, 2026 Q2 2026 BUSINESS UPDATE These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements.

SEC original ↗AbCellera — Presentation / slide deck (8-K exhibit)EX-99Aug 5, 2026